title: Inhibition of morphine tolerance and dependence by MS-153, a glutamate transporter activator.
abstract: We investigated the effects of (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153), which is reported to accelerate glutamate uptake, on the development of morphine tolerance and physical dependence in mice. For the induction of morphine tolerance and dependence, mice were twice daily treated with morphine (10-45 mg/kg, s.c.) for 5 days. First, co-administration of MS-153 (12.5 mg/kg, s.c.) did not affect the morphine's potency for its acute antinociceptive effect (1 and 3 mg/kg, s.c.). Next, co-administrations of MS-153 (1, 3 and 12.5 mg/kg, s.c.) during repeated morphine treatments significantly attenuated the development of tolerance to the antinociceptive effect of morphine (3 mg/kg, s.c.) and suppressed the naloxone (10 mg/kg, i.p.)-precipitated withdrawal signs (jumps and body weight loss). The inhibitory effect of MS-153 on the withdrawal signs was due to the attenuation of the development of dependence rather than that of expression of withdrawal signs. These results suggest that MS-153, a glutamate transporter activator, has an inhibitory effect on the development of morphine tolerance and physical dependence.
authors.affiliation: Department of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, 606-8501, Kyoto, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: T
authors.initials: T
authors.lastname: Ozawa
authors.forename: K
authors.initials: K
authors.lastname: Shige
authors.forename: R
authors.initials: R
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Minami
authors.forename: M
authors.initials: M
authors.lastname: Satoh
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D027322:Amino Acid Transport System X-AG; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D019540:Area Under Curve; D001835:Body Weight / Q000187:drug effects; D004361:Drug Tolerance; D008297:Male; D051379:Mice; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009021:Morphine Dependence; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D018696:Neuroprotective Agents / Q000494:pharmacology; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects; D013997:Time Factors
chemical_list: C101692:5-methyl-1-nicotinoyl-2-pyrazoline; D018528:ATP-Binding Cassette Transporters; D027322:Amino Acid Transport System X-AG; D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D018696:Neuroprotective Agents; D009539:Nicotinic Acids; D009270:Naloxone; D009020:Morphine